Top Tweets for #EASDRME

almost 3 years ago

Thank you for joining #EASDRME at #EASD2023. Don't forget to check out our educational videos on our obesity resource ➡️ https://t.co/kQ4V4ma3Hu @conscienHealth @BevTchangMD @EasoPresident @DrKarlNadolsky @MWeintraubMD ✖️ Not intended for UK and Ireland based Healthcare Physicians #cardiotwitter @radcliffeCARDIO #Obesity #diabetes #cardioed

0

4

2

0

1K

Amelia Carro — Instituto Corvilud @icorvilud

almost 3 years ago

Cost/coverage of indicated meds imo #EASDrme

0

1

0

704

almost 3 years ago

Not to miss these 4 trials #EASD2023 ✍️Excellent coverage by @radcliffeCARDIO ✍️Obesity drugs in patients with/without diabetes ✍️I do also recommend educational hub https://t.co/Ij7lWTQcl3 #EASDRME #CardioTwitter #Cardioed #tirzepatide #survodutide #retatrutide @BevTchangMD

icorvilud's tweet photo. Not to miss these 4 trials #EASD2023
✍️Excellent coverage by @radcliffeCARDIO
✍️Obesity drugs in patients with/without diabetes
✍️I do also recommend educational hub https://t.co/Ij7lWTQcl3
#EASDRME #CardioTwitter #Cardioed #tirzepatide #survodutide #retatrutide
@BevTchangMD https://t.co/lEaY0RB1h7

0

4

2

0

465

Ted Kyle @ConscienHealth

almost 3 years ago

The spotlight shone brighter on #tirzepatide than #semaglutide at #EASD2023 this week. Could it be that sema is already old news? #EASDRME https://t.co/kkW0ZlvKNr

2

10

6

1

2K

Jaime Almandoz, MD MBA FTOS

almost 3 years ago

Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 #Diabetes | @NEJM Hybrid closed-loop therapy significantly improved maternal glycemic control during pregnancy https://t.co/2UpKkLp1vT #easd2023 #easdrme @EASDnews @radcliffeCARDIO

0

5

3

2

716

@JaimeAlmandoz

almost 3 years ago · Hamburg

#EASD2023 🚨SURMOUNT-4🚨 At 88 Weeks: ⚖️Weight loss with #tirzepatide 25.8% 📉≥25% weight loss in >50% #TZP ✅ Effective next-generation #AOM ✅ Durable #weight reduction 📖 Next chapter of #ObesityCare @ConscienHealth @BevTchangMD @MWeintraubMD @DrKarlNadolsky #EASDRME

JaimeAlmandoz's tweet photo. #EASD2023
🚨SURMOUNT-4🚨
At 88 Weeks:
⚖️Weight loss with #tirzepatide 25.8%
📉≥25% weight loss in >50% #TZP
✅ Effective next-generation #AOM
✅ Durable #weight reduction
📖 Next chapter of #ObesityCare
@ConscienHealth @BevTchangMD @MWeintraubMD @DrKarlNadolsky #EASDRME https://t.co/KvbDryraRZ

0

46

17

8

32K

almost 3 years ago

Perhaps secret choice, “all of the above?” #EASDrme

almost 3 years ago

Which of these trials will have the biggest impact on the obesity landscape? (slide in comments) Learn more about #obesity here: https://t.co/kQ4V4ma3Hu @conscienHealth @PrashVas @EasoPresident @DrKarlNadolsky @MWeintraubMD @radcliffeCARDIO #EASDRME #EASD2023 #CardioTwitter #obesity ✖️ Not intended for UK and Ireland based Healthcare Physicians

3

45

9

1

94K

0

2

1

0

690

almost 3 years ago

Which of these trials will have the biggest impact on the obesity landscape? (slide in comments) Learn more about #obesity here: https://t.co/kQ4V4ma3Hu @conscienHealth @PrashVas @EasoPresident @DrKarlNadolsky @MWeintraubMD @radcliffeCARDIO #EASDRME #EASD2023 #CardioTwitter #obesity ✖️ Not intended for UK and Ireland based Healthcare Physicians

3

45

9

1

94K

almost 3 years ago

Surmount 4 gave patients with #obesity #tirzepatide x 36 weeks before randomizing to continued tirzepatide vs placebo @EASDnews #easdrme *over 50% achieving >25% reduction??!! 🤩🤯 #EASD2023

DrKarlNadolsky's tweet photo. Surmount 4 gave patients with #obesity #tirzepatide x 36 weeks before randomizing to continued tirzepatide vs placebo @EASDnews #easdrme
*over 50% achieving >25% reduction??!! 🤩🤯 #EASD2023 https://t.co/MLjJy9FVtt

almost 3 years ago

Results from SURMOUNT-4 just presented. 👉USE #EASDRME TO JOIN THE CONVERSATION 👈 #EASD2023 #Obesity #CardioEd #MedEd #EASDRME @conscienHealth @BevTchangMD @EasoPresident @DrKarlNadolsky @MWeintraubMD @radcliffeCARDIO ✖️ Not intended for UK and Ireland based Healthcare Physicians

radcliffeCARDIO's tweet photo. Results from SURMOUNT-4 just presented.

👉USE #EASDRME TO JOIN THE CONVERSATION 👈

#EASD2023 #Obesity #CardioEd #MedEd #EASDRME

@conscienHealth @BevTchangMD @EasoPresident @DrKarlNadolsky @MWeintraubMD @radcliffeCARDIO

✖️ Not intended for UK and Ireland based Healthcare Physicians

0

7

2

0

9K

1

21

8

1

4K

almost 3 years ago

Results from SURMOUNT-4 just presented. 👉USE #EASDRME TO JOIN THE CONVERSATION 👈 #EASD2023 #Obesity #CardioEd #MedEd #EASDRME @conscienHealth @BevTchangMD @EasoPresident @DrKarlNadolsky @MWeintraubMD @radcliffeCARDIO ✖️ Not intended for UK and Ireland based Healthcare Physicians

0

7

2

0

9K

Michael Weintraub, MD @MWeintraubMD

almost 3 years ago

#Metformin provided glycemic, neonatal benefits for women with gestational #diabetes in this randomized trial. #easdrme ⁦@EASDnews⁩ Dunne F. Metformin for the management of GDM: Friend or foe? Presented #EASD2023 Published in ⁦@JAMA_current⁩ https://t.co/9z8O3kl4Uw

0

2

0

424

almost 3 years ago

In the hot off the press SURPASS-6 study, quality of life measures improved with tirzepatide compared to meal-time insulin lispro SURPASS-6 summary: ⬇️ A1c,⬇️body weight, ⬇️ background insulin ⬇️hypoglycemia ⬆️ GI events #EASDRME @radcliffeCARDIO @EASDnews

MWeintraubMD's tweet photo. In the hot off the press SURPASS-6 study, quality of life measures improved with tirzepatide compared to meal-time insulin lispro

SURPASS-6 summary:
⬇️ A1c,⬇️body weight, ⬇️ background insulin ⬇️hypoglycemia
⬆️ GI events

#EASDRME @radcliffeCARDIO
@EASDnews https://t.co/uQKcqJ2s24

Michael Weintraub, MD @MWeintraubMD

almost 3 years ago

NEW DATA drop: In SURPASS 6, tirzepatide added to insulin glargine in T2DM had greater a1c reduction (⬇️2.1%) than adding meal-time insulin (⬇️1.1%). Tirzepatide ⬇️ 12kg than meal-time insulin and ⬇️ hypoglycemia. And 20 less jabs per week! https://t.co/VHJHRehZFJ #EASDRME

2

106

32

18

17K

0

8

2

1

1K

almost 3 years ago

SURMOUNT-4 being presented at #EASD2023 - 36 week open-label treatment with #tirzepatide followed by 52 weeks of randomization to continued treatment bs placebo #EASDRME @EASDnews

almost 3 years ago

We’re looking forward to seeing data from our selected trial today: SURMOUNT-4 #EASD2023 👉USE #EASDRME TO JOIN THE CONVERSATION 👈 #Obesity #CardioEd #MedEd @conscienHealth @BevTchangMD @EasoPresident @MWeintraubMD ✖️ Not intended for UK and Ireland based Healthcare Physicians #EASD2023 #Obesity #CardioEd #MedEd #EASDRME @radcliffeCARDIO

0

6

2

0

2K

0

2

1

0

835

Michael Weintraub, MD @MWeintraubMD

almost 3 years ago

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 #diabetes and chronic kidney disease: The FINE-ONE trial - @EASDnews #easdrme #easd2023 https://t.co/zmNx9dyuHg

0

3

0

573

almost 3 years ago

#tirzepatide in GADA positive and low c-peptide pts showed ⬇️2% a1c in post-hoc SURPASS analysis. Does this provide more evidence on tirzepatide use in new-onset #type1diabetes? Interesting data at #EASD2023! @BevTchangMD #EASDRME @radcliffeCARDIO

MWeintraubMD's tweet photo. #tirzepatide in GADA positive and low c-peptide pts showed ⬇️2% a1c in post-hoc SURPASS analysis.

Does this provide more evidence on tirzepatide use in new-onset #type1diabetes?

Interesting data at #EASD2023!

@BevTchangMD #EASDRME @radcliffeCARDIO https://t.co/JGK15WviFF

1

95

29

15

14K

Ted Kyle @ConscienHealth

almost 3 years ago

At #EASD2023 yesterday, a collegial but fierce debate about #obesity and #diabetes remissions revealed a bit of bias in presumptions about these conditions. #EASDRME HT: @KamleshKhunti https://t.co/81rvc1n123

2

25

8

1

3K

Daniel J Drucker @DanielJDrucker

almost 3 years ago

GIP receptor agonism added to GLP-1 liraglutide appeared to improve GI tolerance of liraglutide - @EASDnews #EASDRME

almost 3 years ago

Compelling clinical data that a long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves GI tolerability of glucagon-like peptide 1 receptor agonist therapy with liraglutide in healthy participants over 9 days @Filip_Knop #EASD2023 @EASDnews

DanielJDrucker's tweet photo. Compelling clinical data that a long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves GI tolerability of glucagon-like peptide 1 receptor agonist therapy with liraglutide in healthy participants over 9 days @Filip_Knop #EASD2023 @EASDnews https://t.co/pBqDps6dxE

1

60

16

10

9K

0

7

2

0

2K